Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

for
Melanoma, Non-small Cell Lung Cancer,
Location: Fairfax VA, Pittsburgh PA, Grand Rapids MI, St Louis MO,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07115043

Phase 1, Phase 2, Recruiting

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

for
PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Location: Long Island City NY, Philadelphia PA, Sarasota FL,
Sponsor: Whitehawk Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07470853

Phase 1, Recruiting

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

for
Advanced Relapsed or Refractory Germ Cell Tumours,
Location: Houston TX, Los Angeles CA
Sponsor: Boehringer Ingelheim

Sex: All

Age: 18+

Code: NCT07306559

Phase 1, Recruiting

IDOV-Immune for Advanced Solid Tumors

for
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer,
Location: St Louis MO, Houston TX, San Antonio TX
Sponsor: ViroMissile, Inc.

Sex: All

Age: 18+

Code: NCT06910657

Phase 1, Recruiting

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

for
Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
Location: Scarborough ME, Hartford CT, Horsham PA, Towson MD,
Sponsor: Genmab

Sex: Female

Age: 18+

Code: NCT07225270

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for
Endometrial Cancer, Cervical Cancer, Ovarian Cancer,
Location: Boston MA, Mineola NY, Lake Success NY, New York NY,
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT06293898

Phase 1, Recruiting

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

for
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer,
Location: Fairfax VA, Dallas TX
Sponsor: Hefei TG ImmunoPharma Co., Ltd.

Sex: All

Age: 18+

Code: NCT05746897

Phase 1, Recruiting

Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study

for
Ovary Cancer
Location: Knoxville TN
Sponsor: University of Tennessee Graduate School of Medicine

Sex: Female

Age: 18+

Code: NCT06800105

Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

for
Ovarian Cancer, Non-small Cell Lung Cancer
Location: Boston MA, New York NY, East Brunswick NJ, Fairfax VA,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT06303505

Phase 1, Phase 2, Recruiting

Ovarian Dendritic Cell Vaccine Trial

for
Ovarian Cancer
Location: Maywood IL
Sponsor: Loyola University

Sex: Female

Age: 18+

Code: NCT00703105

Phase 2, Recruiting

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

for
Ovarian Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05123807

Phase 2, Recruiting

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

for
Low Grade Ovarian Serous Adenocarcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 0+

Code: NCT00488878

Recruiting

Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer

for
Ovarian Cancer
Location: New Haven CT, Miami FL
Sponsor: Yale University

Sex: Female

Age: 18+

Code: NCT05761561

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

for
Endometrial Cancer, Gastric Cancer,
Location: Commack NY, East Brunswick NJ, Columbus OH,
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT05489211

Phase 2, Recruiting

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

for
Ovarian Cancer, Fallopian Tube Carcinoma, Ovarian Carcinoma,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06290193

Phase 2, Recruiting

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

for
Ovarian Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05636111

Phase 1, Recruiting

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

for
Ovarian Cancer
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: Female

Age: 18+

Code: NCT05952453

Phase 2, Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: Lake Success NY, New York NY, Nashville TN, Westwood KS,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06695845

Phase 2, Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

for
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer,
Location: Boston MA
Sponsor: Brigham and Women's Hospital

Sex: Female

Age: 18+

Code: NCT04701645

Phase 1, Recruiting

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

for
Peritoneal Carcinomatosis, Ovarian Cancer
Location: Tampa FL
Sponsor: Oncoinvent Solutions AS

Sex: Female

Age: 18+

Code: NCT06504147

Phase 2, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial